Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report

Abstract

Considering that targeted cancer therapies become increasingly effective, oncologists should be extremely cautious when treating patients at high risk of tumor lysis syndrome, even if they are not treated with cytotoxic chemotherapy, and determine appropriate prophylaxis.